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Abstract
Dopamine beta-hydroxylase (DβH) deficiency is a very rare form of primary autonomic failure
characterized by a complete absence of noradrenaline and adrenaline in plasma together with
increased dopamine plasma levels. The prevalence of DβH deficiency is unknown. Only a limited
number of cases with this disease have been reported. DβH deficiency is mainly characterized by
cardiovascular disorders and severe orthostatic hypotension. First symptoms often start during a
complicated perinatal period with hypotension, muscle hypotonia, hypothermia and hypoglycemia.
Children with DβH deficiency exhibit reduced ability to exercise because of blood pressure
inadaptation with exertion and syncope. Symptoms usually worsen progressively during late
adolescence and early adulthood with severe orthostatic hypotension, eyelid ptosis, nasal stuffiness
and sexual disorders. Limitation in standing tolerance, limited ability to exercise and traumatic
morbidity related to falls and syncope may represent later evolution. The syndrome is caused by
heterogeneous molecular alterations of the DBH gene and is inherited in an autosomal recessive
manner. Restoration of plasma noradrenaline to the normal range can be achieved by therapy with
the synthetic precursor of noradrenaline, L-threo-dihydroxyphenylserine (DOPS). Oral
administration of 100 to 500 mg DOPS, twice or three times daily, increases blood pressure and
reverses the orthostatic intolerance.
Disease name and synonyms
Dopamine beta-hydroxylase deficiency
Norepinephrine deficiency
Noradrenaline deficiency
Definition/diagnostic criteria
Dopamine beta-hydroxylase (DβH) deficiency is a very
rare form of primary autonomic failure characterized by a
complete absence of noradrenaline and adrenaline in
plasma together with increased plasma dopamine levels.
It was first described in 1986 [1]. This rare congenital dis-
ease is caused by a series of mutations in the DBH gene,
mapped to chromosome 9q34, encoding the key enzyme
in noradrenaline synthesis.
The diagnosis should be suspected when pure sympa-
thetic autonomic failure is associated with absence of
both noradrenaline and adrenaline and accumulation of
dopamine in plasma.
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Epidemiology
The very limited number of cases of DβH deficiency in
humans suggests that the disorder is very rare. However,
since deficiency in DβH has been shown to be lethal in
embryos or shortly after birth in mice [2], the prevalence
of the disorder may be higher than expected. It should be
kept in mind that history of spontaneous abortions and
stillbirths has been noted in parents of DβH deficient
patients. Among the cases reported, one family only con-
tained two members presenting with the disease [3].
Etiology
Despite the fact that the DBH gene was cloned a long time
ago [4], the molecular defects in DβH deficiency are
poorly understood. Access to extensive data concerning
the DBH gene is available on the Internet [5]. In three
unrelated patients, a common mutation has been identi-
fied in intron 1 (IVS1+2T→C) leading to aberrant splicing
and a premature stop codon probably involved in
noradrenaline deficiency [3,6]. In one patient, a mutation
in exon 4 (764G>T) that leads to alteration of a sequence
specific to copper type II ascorbate-dependent monooxy-
genase was also described [3]. A summary of identified
mutations in the DBH gene is given in Table 1. However,
these mutations cannot entirely explain the phenotype,
since some of them are also found in healthy subjects [7].
It is possible, for instance, that the combination of the
IVS1+2T→C mutation with other missense mutations is
necessary for clinical expression of the disorder. Clearly,
further studies are needed to explain how the identified
mutations can lead to the absence of detectable enzyme
protein [for a review see ref [8]].
From a pathophysiological point of view, whatever the
nature of the mutations leading to DβH enzyme inactiv-
ity, the consequence in patients is a large accumulation of
dopamine, the precursor of noradrenaline, in sympathetic
nerves. This biochemical pattern probably explains cardi-
ovascular paradoxical responses such as increase in
dopamine but not in noradrenaline levels with standing
or during hypoglycemia or tyramine infusion. It is, how-
ever, rather surprising, in view of the role of central nerv-
ous system DβH in mood and behavior [8,9], that only
mild behavioral changes have been reported in DβH
patients.
Clinical description
The available data come from clinical descriptions of the
reported cases (see Table 2). First symptoms often start
during a complicated perinatal period with hypotension,
muscle hypotonia, hypothermia and hypoglycemia.
Delay in opening of the eyes, ptosis of eyelids and vomit-
ing have also been reported. Children with DβH defi-
ciency exhibit reduced ability to exercise because of blood
pressure inadaptation with exertion and syncope. Symp-
toms usually progressively worsen during late adolescence
and early adulthood with severe orthostatic hypotension,
eyelid ptosis, nasal stuffiness and sexual disorders.
Examination indicates low blood pressure in standing
position, small but light- and accommodation-reactive
pupils and normal sweating. Mild behavioral changes
have also been reported in some patients. Some biochem-
ical abnormalities have also been reported such as hypo-
Table 1: Summary of discovered mutations in DBH gene (extracted from http://www.genetest.org).
Nucleotide change Location Amino acid change Mutation type
C-1021T 5' flanking Noncoding
G259A Exon 1 V87M Missense
IVS1+2T→C Intron 1 Noncoding
C300A Exon 2 D100E Missense
IVS3+8C→T Intron 3 Noncoding
G991A Exon 6 D331N Missense
IVS10+415A0→G Intron 10 Noncoding
Table 2: Main clinical characteristics of DβH deficiency. Adapted 
from Robertson D et al., 1991 [13].
Feature (%)
Severe orthostatic hypotension 100
Impaired ejaculation 100
Ptosis of eyelids 67
Complicated perinatal course 67
Nocturia 67
Hyperextensible/hyperflexible joints 50
High palate 50
Nasal stuffiness 50
Mild behavioral changes 33
Seizures (with hypotension) 33
Bradydactyly 33
Sluggish tendon reflexes 33
Weak facial musculature 33
Hypotonic skeletal muscles 33
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prolactinemia, hypomagnesemia and raised blood urea
nitrogen.
Diagnostic methods
The clinical exploration of autonomic nervous system
activity indicates a pure and isolated sympathetic failure
with normal cholinergic function. Orthostatic hypoten-
sion is profound, and blood pressure does not increase as
expected during usual tests such as Valsalva manoeuvre
(phase IV), isometric handgrip or cold exposure. When
pharmacological testing is performed, some responses
clearly indicate adrenergic cardiac and vascular receptor
supersensitivity. Drug challenge confirms the sympathetic
failure with a lack of pressor response to tyramine or a sig-
nificant and apparently paradoxical elevation of blood
pressure with clonidine.
Since the key enzyme that catalyses the conversion of
dopamine to noradrenaline, DβH, is undetectable in 4%
of the population with normal concentrations of catecho-
lamines [12], definite diagnosis of DβH deficiency is evi-
dent when plasma levels of catecholamines and
metabolites are measured. In DβH deficient patients, cir-
culating levels of noradrenaline and adrenaline are unde-
tectable, whereas dopamine levels are elevated [13].
Metabolites of noradrenaline are absent in plasma, urine
and cerebro-spinal fluid.
Differential diagnosis
A typical flare reaction to intradermal histamine together
with normal tearing sensory function, normal taste and
smell, normal intact corneal and deep tendon reflexes,
and lack of Askenazi Jewish extraction allow exclusion of
familial dysautonomia [10]. Absence of profound mental
retardation or hypopigmentation makes confusion with
Menkes syndrome improbable [11].
Genetic counseling
DβH deficiency is inherited in an autosomal recessive
manner [6]. At conception, the sibs of an affected individ-
ual have a 25% chance of being affected, a 50% chance of
being asymptomatic carriers, and a 25% chance of being
unaffected and not carriers. The optimal time for determi-
nation of genetic risk is before pregnancy. DBH molecular
genetic testing is available on a research basis only.
Management including treatment
As orthostatic hypotension is the main symptom of
patients with DβH deficiency, most of the available infor-
mation on treatment focuses on this aspect. Many empir-
ical therapies using mineralocorticoids or adrenergic
receptor agonists have been reported to have mild effects.
As the underlying biochemical defect has been identified,
dihydroxyphenylserine (L-threo-3,4-dihydroxyphenylser-
ine, L-Threo-DOPS, DOPS), a synthetic precursor of
noradrenaline, is the treatment of choice. DOPS has been
proposed for management of the orthostatic hypotension,
with controversial results [14]. Administration of DOPS
in mice lacking the Dbh gene restores plasma noradrena-
line levels to normal and reverses behavioral abnormali-
ties [15]. Restoration of the sensitivity to antidepressants
has been demonstrated in the same model [9]. In humans
with DβH deficiency, L-Threo-DOPS administration
results in dramatic increase in blood pressure and relief of
postural symptoms [16].
Prognosis
Little is known about prognosis. Retrospective data indi-
cate that in most described cases, the perinatal period is
complicated by episodes of hypotension, hypoglycemia
and hypothermia. Later evolution seems to be marked by
progressive orthostatic hypotension with limitation in
standing tolerance, limited ability to exercise and trau-
matic morbidity related to falls and syncope. L-threo-
DOPS has been described as being very effective for restor-
ing noradrenergic tone and correcting postural hypoten-
sion [1]. Effects of L-threo-DOPS on other aspects of
autonomic failure have not been reported.
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